Clascoterone
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Clascoterone |
| DrugBank ID | DB12499 |
| Brand Names (EU) | Winlevi |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 94.82% |
Approved Indication (EMA)
Adults Winlevi is indicated for the treatment of acne vulgaris. Adolescents (from 12 to < 18 years of age) Winlevi is indicated for the treatment of facial acne vulgaris.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | candidiasis | 94.82% | DL |
| 2 | migraine disorder | 92.11% | DL |
| 3 | migraine with brainstem aura | 91.39% | DL |
| 4 | migraine with or without aura, susceptibility to | 89.40% | DL |
| 5 | leprosy | 88.87% | DL |
| 6 | atrophoderma vermiculata | 86.78% | DL |
| 7 | oral candidiasis | 86.71% | DL |
| 8 | progeria-short stature-pigmented nevi syndrome | 86.02% | DL |
| 9 | adrenal gland hyperfunction | 85.90% | DL |
| 10 | multiple endocrine neoplasia | 85.51% | DL |
| 11 | ulerythema ophryogenesis | 85.35% | DL |
| 12 | progeroid syndrome, Petty type | 85.25% | DL |
| 13 | commissural lip fistula | 84.89% | DL |
| 14 | osteoradionecrosis of the mandible | 84.86% | DL |
| 15 | burning mouth syndrome | 84.83% | DL |
| 16 | oral leukoedema | 84.83% | DL |
| 17 | hyperargininemia | 84.79% | DL |
| 18 | carbamoyl phosphate synthetase I deficiency disease | 84.79% | DL |
| 19 | Leydig cell hypoplasia due to LH resistance | 82.66% | DL |
| 20 | bone marrow neoplasm | 82.59% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.